Effect of valproate on cerebral metabolism and blood flow: An 18F-2-deoxyglusose and 15O water positron emission tomography study

William D. Gaillard, Thomas Zeffiro, Shahin Fazilat, Charles DeCarli, William H. Theodore

Research output: Contribution to journalArticle

97 Scopus citations


We compared the effect of valproate (VPA) on cerebral metabolic rate for glucose (CMRGlc) and cerebral blood flow (CBF), measured with 18F-2-deoxyglucose (18FDG) and 15O water positron emission tomography (PET), in 10 normal volunteers. Mean VPA dose was 17.7 mg/ks, and mean VPA level was 82.1 mg/L (±16.5) for 4 weeks. VPA reduced global CMRGlc by 9.4% (9.60 ± 0.76 vs. 8.59 ± 1.02 mg Glc/min/100 g. p < 0.05) and regionally in all anatomic areas (p < 0.05 for 11 of 26 areas). VPA diminished global CBF by 14.9% (56.55 ± 6.70 vs. 47.48 ± 4.42 ml/min/100 g, p < 0.002) and regionally in all anatomic areas (p < 0.05 for 12 of 26 areas). No significant correlation was noted between VPA level and either global CMRGlc or CBF. The effect of VPA on global CMRGlc is similar to that of carbamazepine (CBZ) and phenytoin but less than that of phenobarbital, valium, or combination therapy with VPA and CBZ. VPA reduced regional CBF (rCBF) but not CMRGlc in the thalamus, an effect that may be associated with VPA's mechanism of action against generalized seizures.

Original languageEnglish (US)
Pages (from-to)515-521
Number of pages7
Issue number6
StatePublished - Jun 1996
Externally publishedYes



  • Cerebral blood flow
  • Cerebral metabolism
  • Positron emission tomography
  • Valproate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this